Journal
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION
Volume 118, Issue 541, Pages 43-55Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/01621459.2022.2110876
Keywords
ACE2; Cell type-specific association; COVID-19; Mixture model; Proteomics
Categories
Ask authors/readers for more resources
This study proposes a statistical framework called iProMix to analyze the interaction between ACE2 protein and other proteins/pathways, and applies this framework in lung adenocarcinoma research to identify significant pathways associated with ACE2 protein abundances in epithelial cells.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused over six million deaths in the ongoing COVID-19 pandemic. SARS-CoV-2 uses ACE2 protein to enter human cells, raising a pressing need to characterize proteins/pathways interacted with ACE2. Large-scale proteomic profiling technology is not mature at single-cell resolution to examine the protein activities in disease-relevant cell types. We propose iProMix, a novel statistical framework to identify epithelial-cell specific associations between ACE2 and other proteins/pathways with bulk proteomic data. iProMix decomposes the data and models cell type-specific conditional joint distribution of proteins through a mixture model. It improves cell-type composition estimation from prior input, and uses a nonparametric inference framework to account for uncertainty of cell-type proportion estimates in hypothesis test. Simulations demonstrate iProMix has well-controlled false discovery rates and favorable powers in nonasymptotic settings. We apply iProMix to the proteomic data of 110 (tumor-adjacent) normal lung tissue samples from the Clinical Proteomic Tumor Analysis Consortium lung adenocarcinoma study, and identify interferon alpha/gamma response pathways as the most significant pathways associated with ACE2 protein abundances in epithelial cells. Strikingly, the association direction is sex-specific. This result casts light on the sex difference of COVID-19 incidences and outcomes, and motivates sex-specific evaluation for interferon therapies. for this article are available online.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available